These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36312586)

  • 1. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.
    Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
    Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 3. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
    Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
    BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas.
    Zhu H; Wan Q; Tan J; Ouyang H; Pan X; Li M; Zhao Y
    Front Genet; 2022; 13():992995. PubMed ID: 36579333
    [No Abstract]   [Full Text] [Related]  

  • 5. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.
    Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W
    Front Genet; 2022; 13():939956. PubMed ID: 36105090
    [No Abstract]   [Full Text] [Related]  

  • 6. Cuproptosis-Related Genes Are Associated with Cell Cycle and Serve as the Prognostic Signature for Clear Cell Renal Cell Carcinoma.
    Guo T; Zhang J; Yuan Z; Tang H; Wang T; Wang X; Chen S
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
    Zhou C; Li C; Zheng Y; Huang X
    Front Oncol; 2022; 12():934076. PubMed ID: 36387247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
    Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
    Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
    Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer.
    Xu QT; Wang ZW; Cai MY; Wei JF; Ding Q
    Front Pharmacol; 2022; 13():1115608. PubMed ID: 36699089
    [No Abstract]   [Full Text] [Related]  

  • 13. Pan-cancer profiles of the cuproptosis gene set.
    Liu H
    Am J Cancer Res; 2022; 12(8):4074-4081. PubMed ID: 36119826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
    Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
    Front Genet; 2023; 14():1094793. PubMed ID: 36891150
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.
    Zhou J; Chen D; Zhang S; Wang C; Zhang L
    Front Genet; 2022; 13():1039983. PubMed ID: 36712848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma.
    Chen Y; Zou X; Ma M; Liu Y; Wang R; Dai Z; Tashiheng Y; Yan Y; Yu X; Wang X; Liu C; Lin X; Cheng H
    Curr Oncol; 2023 Jan; 30(2):1648-1662. PubMed ID: 36826087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.